These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 37924725

  • 1. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress.
    Lu Y, Chan YT, Wu J, Feng Z, Yuan H, Li Q, Xing T, Xu L, Zhang C, Tan HY, Lee TK, Feng Y, Wang N.
    Drug Resist Updat; 2023 Nov; 71():101015. PubMed ID: 37924725
    [Abstract] [Full Text] [Related]

  • 2. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
    Lu Y, Chan YT, Tan HY, Zhang C, Guo W, Xu Y, Sharma R, Chen ZS, Zheng YC, Wang N, Feng Y.
    J Exp Clin Cancer Res; 2022 Jan 03; 41(1):3. PubMed ID: 34980204
    [Abstract] [Full Text] [Related]

  • 3. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z, Xia S, Liang Y, Ji L, Pan Y, Jiang S, Wan Z, Tao L, Chen J, Lin C, Liang X, Xu J, Cai X.
    Theranostics; 2020 Jan 03; 10(19):8834-8850. PubMed ID: 32754282
    [Abstract] [Full Text] [Related]

  • 4. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC.
    Chan YT, Wu J, Lu Y, Li Q, Feng Z, Xu L, Yuan H, Xing T, Zhang C, Tan HY, Feng Y, Wang N.
    Mol Cancer; 2024 Apr 06; 23(1):74. PubMed ID: 38582885
    [Abstract] [Full Text] [Related]

  • 5. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z, Ye X, Ma X, Hu X, Yang W, Shi J, Chen G, Gong L.
    Cancer Med; 2020 Jun 06; 9(12):4324-4338. PubMed ID: 32324343
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR.
    Ji L, Lin Z, Wan Z, Xia S, Jiang S, Cen D, Cai L, Xu J, Cai X.
    Cell Death Dis; 2020 Apr 20; 11(4):250. PubMed ID: 32313144
    [Abstract] [Full Text] [Related]

  • 10. Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma.
    Shao YY, Chen PS, Lin LI, Lee BS, Ling A, Cheng AL, Hsu C, Ou DL.
    Br J Cancer; 2022 Jun 20; 126(12):1806-1814. PubMed ID: 35236936
    [Abstract] [Full Text] [Related]

  • 11. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
    Li TT, Mou J, Pan YJ, Huo FC, Du WQ, Liang J, Wang Y, Zhang LS, Pei DS.
    J Biomed Sci; 2021 Aug 02; 28(1):56. PubMed ID: 34340705
    [Abstract] [Full Text] [Related]

  • 12. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.
    Zhang K, Chen J, Zhou H, Chen Y, Zhi Y, Zhang B, Chen L, Chu X, Wang R, Zhang C.
    Cell Death Dis; 2018 Feb 22; 9(3):312. PubMed ID: 29472524
    [Abstract] [Full Text] [Related]

  • 13. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
    Kumar M, Kaur R, Kanthaje S, Dhiman RK, Chakraborti A.
    J Cancer Res Clin Oncol; 2023 Aug 22; 149(9):5823-5839. PubMed ID: 36583742
    [Abstract] [Full Text] [Related]

  • 14. MiR-3677-3p promotes development and sorafenib resistance of hepatitis B-related hepatocellular carcinoma by inhibiting FOXM1 ubiquitination.
    He H, Zhou J, Cheng F, Li H, Quan Y.
    Hum Cell; 2023 Sep 22; 36(5):1773-1789. PubMed ID: 37402927
    [Abstract] [Full Text] [Related]

  • 15. MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma.
    Gramantieri L, Pollutri D, Gagliardi M, Giovannini C, Quarta S, Ferracin M, Casadei-Gardini A, Callegari E, De Carolis S, Marinelli S, Benevento F, Vasuri F, Ravaioli M, Cescon M, Piscaglia F, Negrini M, Bolondi L, Fornari F.
    Cancer Res; 2020 Apr 15; 80(8):1720-1734. PubMed ID: 32015093
    [Abstract] [Full Text] [Related]

  • 16. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.
    Zhang Y, Pan Q, Shao Z.
    Hum Cell; 2023 Jan 15; 36(1):296-311. PubMed ID: 36424471
    [Abstract] [Full Text] [Related]

  • 17. Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.
    Xu C, Sun W, Liu J, Pu H, Li Y.
    Pathol Res Pract; 2023 May 15; 245():154435. PubMed ID: 37075641
    [Abstract] [Full Text] [Related]

  • 18. miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
    de la Cruz-Ojeda P, Schmid T, Boix L, Moreno M, Sapena V, Praena-Fernández JM, Castell FJ, Falcón-Pérez JM, Reig M, Brüne B, Gómez-Bravo MA, Giráldez Á, Bruix J, Ferrer MT, Muntané J.
    Cells; 2022 Aug 28; 11(17):. PubMed ID: 36078082
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, Zhang Y.
    PLoS One; 2014 Aug 28; 9(12):e115565. PubMed ID: 25531114
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.